Live Attenuated Vaccines are a type of vaccine that contains weakened forms of the pathogen, typically viruses, which are still capable of replicating within the body but cause little to no disease. These vaccines are created by passaging the virus through a series of host cells or by genetically modifying the virus to reduce its virulence while maintaining its ability to stimulate an immune response. Live attenuated vaccines offer several advantages over other types of vaccines. They closely mimic natural infection, triggering a robust immune response that provides long-lasting immunity. In many cases, a single dose of a live attenuated vaccine is sufficient to confer protection against the targeted disease, eliminating the need for booster doses.
Some of the most well-known live attenuated vaccines include those for measles, mumps, rubella (MMR), varicella (chickenpox), yellow fever, oral polio vaccine (OPV), and rotavirus. These vaccines have been highly effective in controlling and even eradicating diseases that were once widespread and deadly. Despite their effectiveness, live attenuated vaccines may not be suitable for certain individuals, such as those with weakened immune systems or pregnant women, who may be at risk of developing severe or adverse reactions. Additionally, live attenuated vaccines require careful handling and storage to maintain their potency, as they can lose efficacy if exposed to high temperatures or mishandled during storage and administration.
Overall, live attenuated vaccines have been instrumental in reducing the burden of infectious diseases and saving countless lives worldwide. By closely mimicking natural infection and stimulating a robust immune response, these vaccines play a crucial role in protecting individuals and communities from a variety of preventable diseases.
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Tubercular disease in children: Optimizing treatment strategies through disease insights
Elena Chiappini, University of Florence, Italy
Title : Approaches towards developing and establishing a biomanufacturing research & development, and manufacturing industry in Zimbabwe: A review of the need, potential funding sources, policy development and implementation
Elliot Nyagumbo, Midlands State University, Zimbabwe
Title : Racial disparities in pediatric pneumonia in Brazil: The role of structural racism forging inequalities in acess to vaccines
Livia Daflon Silva, Federal University of State of Rio de Janeiro, Brazil
Title : Capillary electrophoresis for adjuvanted multivalent recombinant vaccine purity determination
Ashley Prout, Merck, United States